Tumors of the Urinary Tract Flashcards
Incidence of canine urinary bladder tumors?
2%
List 7 risk factors associated with canine bladder tumors?
exposure to flea control (old versions), lawn chemicals and cytoxan, obesity, female gender, neuter status, and a very strong breed predisposition on (OR vs mixed breed: Scotties 21x, Eskimo 6.6x, Shelties 6x, Westies 5.8x).
What can lower the risk for bladder tumors?
Eating vegetables (>3x/week).
Most common bladder tumor?
Other less common bladder tumors?
invasive urothelial carcinoma (iUC) or iTCC is the most common canine UB cancer
less frequent tumors - SCC, adenocarcinoma, undifferentiated carcinoma, rhabdomyosarcoma, LSA, HSA, fibroma and sarcomas.
What is the proposed tumor grade for TCC?
High or 3=70%, intermediate or 2=29%, and low or 1=1% (n=232 iUCs, Knapp, ILAR J, 2014)
What % of tumors extend to urethra and prostate?
56%, 29%
What % have regional LN and distant mets at time of diagnosis?
16%, 14%
What % have mets to lungs?
50%
Other locations of metastasis for TCC?
liver, adrenals, spleen, heart, GI tract, brain and bone (9-14%), +/- skin (seeding or extension).
Why do TCC patients have elevated BUN?
Abnormal urea transporters in the tumor
BRAFv5952 mutation is present in the urine of ___% of canine iUC ?
>80% (19/23 iUC vs 0/37 normal UB or cystitis)
List 5 other DDx to consider for common presenting clinical signs for iUC?
chronic bacterial, granulomatous or polypoid cystitis, urethritis, calculi or other neoplasia
What are 2 IHC markers for iUC?
Uroplakin II +/-GATA-3 can be used to define urothelial origin.
What % of bladder can be safely resected?
50%
Important studies:
n Marvel, et al VCO 2017: n=37 dogs - partial cystectomy + NSAID +/- chemo, DFI=235 (8 mo) and MST=348 days (12 mo). Subset of n=22 dogs - surgery + piroxicam SID +/- chemo, MST=722 days (24 mo)
Knapp, et al ILAR J2014: n=9 dogs 4 surgery (3=complete margins) + deracoxib SID, MST=749 days.
Upton, et at JAVMA 2006: Transurethral CO2 laser ablation + NSAID + chemo, outcome not better than medical therapy alone and risks include urethral perforation and stenosis.
What is the MST with stent placement?
Variable. MST=20-78 days (2-536) from urethral stent placement in one study of iUC and prostatic carcinoma, and MST=57 days in one study with ureteral stents.
Follow up with adjuvant therapy (NSAID, chemo, RT) is strongly recommended and has been noted to improve MST=251 (8-536) (Blackburn, JAVMA 2013).